12:00 AM
Dec 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Liposomal Grb-2: Phase I amended

Bio-Path amended a dose-escalation Phase I trial evaluating IV BP-100-1.01 to include additional higher-dose cohorts due to the compound's "favorable safety profile." The trial, which has evaluated 5, 10, 20 and 40 mg/m 2 doses, plans to include...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >